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Biological advances have radically expanded our insights into the underpinnings of health and 
disease. New knowledge has formed the substrate for translation - expedited in turn by the 
biotechnology and pharmaceutical industry into novel therapeutic solutions impacting the 
management of patients and populations. Indeed, this Bioinnovation Enterprise has become 
the dominant growth sector in drug development and the engine driving the translation of 
breakthrough therapies worldwide. This annual Therapeutic Innovations issue highlights 
recent exceptional advances by the Bioinnovation Enterprise in translating molecular insights 
in pathobiology into transformative therapies. 
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Changes call for innovation, and innovation leads to progress 
Li Keqiang 
The revolution in biological discovery and previously unanticipated strides in technology 
are transforming patient management and healthcare delivery.1 This transformation reflects 
the logarithmic growth in molecular innovation driven by public investment in creating 
platforms for healthcare solutions that benefit populations, now and for future generations.2 
This scientific evolution propels the development of precision solutions, exploiting insights in 
pathophysiology at the molecular level that provides mechanism-based targets for advanced 
therapies, amplifies the ability to affect cures, and eliminates adverse events.3 Indeed, the 
growing toolbox of next-generation platforms has produced unprecedented opportunities to 
personalize pharmacological and technological therapies that can be positioned across the 
spectrum of diseases, populations, and geographies to reach the global community.4 In turn, 
the emerging framework established by molecularly targeted diagnostic and therapeutic 
paradigms transforms the traditional one-size-fits-all approach to patient management into 
individualized healthcare solutions.5 
The profound impact of this scientific revolution on global health can best be 
appreciated by considering the overwhelming success of the output of therapeutic innovation 
in the biotechnology and biopharmaceutical sector recently highlighted in this journal.6 Indeed, 
in the last 30 years, this “Bioinnovation Enterprise” has emerged as one of the largest growth 
sectors in drug development, with >200 therapies emerging for >250 indications from >4,000 
biotechnology companies worldwide with a combined value of $185 billion. In 2012, 
biotechnology product sales worldwide were an estimated $163 billion, which constituted 
~19% of the total prescription product sales. Of 119 overall products categorized as 
blockbusters (sales over $1 billion per year), 47 (39%) were biotechnology products. The 
prominence of this sector in therapeutic innovation is reflected by the fact that the 
overwhelming majority of new molecular entities approved by the FDA over the last 3 years, 
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and those predicted to transform the care of patients in their respective disease classes, are 
products of the evolving Bioinnovation Enterprise.7, 8 
Case in point, the impact of this innovation is highlighted by emerging paradigms for the 
management of asthma.9 This disease currently afflicts 300 million people globally, a number 
which is expected to rise to 400 million by 2020. While most patients are satisfactorily 
controlled on established treatments, 5% remain poorly controlled. In that context, innovative 
treatments have the potential to provide options for these unfortunate patients. Moreover, the 
economic and healthcare benefits of treating poorly controlled asthma are substantial and in 
Europe the total cost of asthma is ~€17.7 billion. Mitchell, El-Gammal, and O’Byrne9 highlight 
how this field has been transformed by mechanistic insights gained in molecular mechanisms 
underlying epithelial inflammation. Allergens bind to surface receptors on bronchial epithelial 
cells releasing a number of cytokines which initiate inflammatory cascades. They mobilize and 
activate inflammatory T cells, eosinophils, and basophils which secrete other cytokines, 
promoting IgE synthesis from B-cells and increasing airway hyper-responsiveness, mucus 
hypersecretion and airway remodeling that are canonical features of allergic asthma. The 
identification of these cytokines, their receptors, and their roles in the inflammatory cascade 
have yielded targets for humanized monoclonal antibodies that interrupt select pathways 
essential to the pathobiology of allergic asthma. There are more than 20 therapeutic 
monoclonal antibodies either approved or in various stages of clinical development that target 
molecular components of the inflammatory cascade. Progression of these agents through their 
developmental programs will transform the management of refractory allergic asthma globally. 
Beyond airways, insights in cytokine cascades mediating inflammation has provided 
remarkable opportunities in the management of inflammatory bowel disease (IBD), including 
Crohn’s disease (transmural inflammation) and ulcerative colitis (mucosal inflammation).10 This 
continuum of diseases afflicts about 10,000 new patients each year, with a prevalence of about 
500,000 patients in the U.S. The most impactful advance in the management of IBD over the past 
20 years has been the development of monoclonal antibodies directed to tumor necrosis factor 
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alpha (TNF-α). Unfortunately, although anti-TNF agents are effective, only ~50% of patients achieve 
clinical remission, long term corticosteroid-free remission rates are only 20-30%, and there is a 
significant loss of response reflecting the formation of neutralizing antibodies. Moreover, while 
anti-TNF agents reduce inflammation, they do not block the underlying pathogenic triggers and 
treatment cessation is associated with disease within one year in more than 50% of patients. These 
considerations highlight the unmet clinical need for novel agents to manage IBD. While approaches 
in clinical development include monoclonal antibodies to inflammatory cytokines, Vanhoe, Nys, and 
Vermiere10 review other novel approaches that leverage recent mechanistic insights into molecular 
mechanisms underlying mucosal inflammation. Indeed, IBD is characterized by the influx of 
immune cells into inflamed sites in the mucosa mediated by adhesion molecules suggesting the 
potential therapeutic value of strategies targeting anti-leukocyte migration. Vedolizumab, a 
monoclonal antibody targeting α4β7 ligand which is responsible for the trafficking of 
lymphocytes to the inflamed gut, was recently approved by US and European regulatory 
agencies and is a major advance for the management of patients with IBD.8, 10 Similarly, 
transforming growth factor (TGF)-β is a cytokine mediating counter-regulatory mechanisms 
modulating inflammation. In turn, the anti-inflammatory effects of TGF-β are blunted by over-
expression of SMAD7 in IBD. Mongersen is an antisense oligonucleotide developed to suppress 
the expression of SMAD7 and reveal the anti-inflammatory effects of TGF-β. Indeed, a recent 
phase II trial of Mongersen led to a clinical response that was sustained for over three months, 
indicating enduring therapeutic effects. As further molecular insights are gained into the 
pathophysiological mechanisms of IBD, next-generation therapies will be directed to 
modulating the mucosal barrier, microbiota, and endoplasmic reticulum stress.10 
Worldwide, atherosclerotic cardiovascular disease (ASCVD) is one of the leading causes 
of death, and in the U.S. accounts for ~$ 315 billion health care expenditure each year. One key 
conceptual advancement in efforts to optimally manage ASCVD was the role of atherosclerotic 
plaques in the pathophysiology of ischemic vascular disease and the relationship between 
circulating levels of cholesterol and plaque formation. Indeed, inhibiting plaque formation by 
6 
 
controlling serum cholesterol levels is one of the essential therapeutic strategies to prevent 
ASCVD and cardiovascular mortality. In that context, the field was transformed by the 
molecular discovery 40 years ago that statins could inhibit HMGCoA reductase, the rate-limiting 
enzyme in the de novo synthesis of cholesterol. This was a breakthrough in the management of 
hypercholesterolemia syndromes, and statins are first line therapy to reduce serum cholesterol 
levels and the incidence of ASCVD and cardiovascular mortality. However, many patients 
experience muscle symptoms and other adverse events that limit compliance. Further, ~70% do 
not attain LDL-C treatment targets even when adherent to statin therapy. Moreover, recent 
practice guidelines recommend statin therapy that expands the populations requiring adequate 
control of serum cholesterol, doubling the number of patients to about 13 million, and the 
associated cost of treatment. These considerations underscore the need for improved therapies 
to control serum cholesterol and ASCVD. This field recently has been transformed again, and 
Shantha and Robinson11 describe the 2003 discovery of PCSK-9 as a novel enzyme expressed in 
liver, intestine, kidney and the nervous system. It resides in a complex with LDL receptors 
enhancing endosomal and lysosomal degradation of those receptors. Gain of function 
mutations of PCSK-9 reduce LDL receptors on the cell surface, resulting in familial 
hypercholesterolemia associated with increased ASCVD. Conversely, patients with loss of 
function mutations in PCSK-9 have elevated amounts of LDL receptors at the cell surface, with 
reduced circulating levels of cholesterol and reduced risk for ASCVD. Based on these novel 
mechanistic insights, monoclonal antibodies that inhibit PCSK-9 were developed as a treatment 
to raise cell surface LDL receptors and lower circulating cholesterol levels and ASCVD risk. 
Indeed, alirocumab and evolocumab reduce serum cholesterol in statin-naïve and statin-
resistant patients. Moreover, meta-analyses suggest that these agents significantly reduce 
ASCVD and overall mortality, without significant treatment-related adverse events. Alirocumab 
and evolocumab were approved in the summer of 2015 for patients on maximal statin therapy 
with familial hypercholesterolemia or cardiovascular disease who might benefit from additional 
cholesterol lowering. 
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Beyond the formation of cholesterol plaques, the other key component contributing to 
the pathophysiology of ASCVD is platelet activation and the formation of thrombi which 
occlude affected vessels. Molecular dissection of platelet signaling has revealed key points of 
intervention to reduce platelet activation and thrombus formation. Contact with a plaque 
induces receptor-mediated platelet adherence and deposition. Subsequent release of ADP and 
thromboxane cause the rapid activation and local recruitment of additional platelets. In turn, 
the activated platelet plasma membrane serves as a critical receptor and cofactor for initiating 
coagulation with the ultimate generation of thrombin enabling formation of an insoluble, cross-
linked fibrin clot. While normal hemostasis ensues when the platelet-fibrin thrombus seals 
wound, thrombus formation in the context of an atherosclerotic plaque produces pathologic 
vessel occlusion. First generation approaches to blocking thrombus formation leveraged the 
discovery that thromboxane, a key mediator of platelet activation, was synthesized from 
arachidonic acid through a cascade in which cyclooxygenase was a rate limiting enzyme. Thus, 
aspirin, an irreversible inhibitor of cyclooxygenase, is one mainstay of therapy to prevent 
platelet activation and clot formation. The field was propelled by the discovery of the role of 
P2Y purinergic receptors in mediating ADP-dependent platelet activation, and agents that block 
these receptors have transformed therapeutic paradigms that prevent thrombus formation. 
However, while these paradigms provide clinically significant improvements in the anti-
thrombotic management of patients with ASCVD, absolute reduction in thrombotic events 
remains relatively low and is associated with a substantial risk of major bleeding. In their 
review, Bray and Holinstat12 describe next-generation molecular insights which are providing 
advanced tools to manage thrombotic disease. Thus, thrombin activation is the final key step in 
the coagulation pathway and a significant regulatory step in platelet activation. Platelets 
express unique G-protein coupled protease-activated receptors (PARs) which are activated 
when thrombin binds to and cleaves the amino-terminus, initiating a cascade of intracellular 
calcium signaling mediating platelet activation. Recognition of the importance of PARs in 
platelet activation and thrombus formation was rapidly translated in a biopharmaceutical 
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program to develop orally-available receptor antagonists. In the summer of 2014, the first PAR 
antagonist, vorapaxar, was approved by the FDA to prevent recurrent cardiovascular events in 
patients with a history of ASCVD. 
These examples underscore the evolving significance of the Bioinnovation Enterprise in 
translating molecular discoveries in the laboratory into novel healthcare paradigms that 
transform disease therapy and prevention in patients and populations. This significance is 
further highlighted by George, Vaid and Summer13 who review the recent approval of 
nintedanib and pirfenidone for the treatment of idiopathic pulmonary fibrosis. Following 
decades of unfruitful exploration, these inhibitors of inflammation, fibroblast function and 
collagen deposition are the first approved treatments for this devastating disease and 
considered to be highly impactful.8 On the horizon, emerging platform technologies are moving 
from the laboratory bench to the bedside to transform our most basic concepts of patient 
management. In that context, Subbotina et al.14 review the promise of morpholino 
oligonucleotides for gene editing to correct what was previously considered to be irreversible 
disease-causing mutations. Further, advances in biology are complemented by innovations in 
bioengineering, and Iezzi15 reviews transformative progress at the interface of brain and 
machine in the form of retinal implants to restore vision. Additionally, acceleration of 
translation reflecting the revolution in biology, in turn, drives the evolution of companion 
structures required to maximize the impact of these transformative discoveries. Berry16 
provides a cogent review of innovations in clinical trial designs that optimizes drug efficacy with 
molecular and pathophysiological disease subtype. Moreover, Fujita17 describes innovations in 
regulatory sciences in Japan to overcome the unique challenges of deploying regenerative cell 
therapies to patients and populations. 
The Bioinnovation Enterprise is poised to transform the rapid pace of knowledge 
generation in pathobiology into therapeutic innovations for global populations. The impact of 
this transformation on the drug development and healthcare delivery landscapes will 
undoubtedly escalate over the coming years, driven by the dual engines of exponential 
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knowledge growth and commoditized technologies with de-risking pipeline development and 
de-escalating costs. One cautionary note in this otherwise optimistic paradigm is indeed the 
cost of this remarkable innovation to individuals and society. For diseases involving millions of 
patients and transformative therapies priced at $10,000 to $100,000 a year, the 
unsustainability of the model is revealed by simple arithmetic. Biopharmaceutical executives, 
investors, third party payors and governmental agencies must collaborate to define the 
appropriate balance between individual patient health, society’s best interests, and a fair 
return on investment that will propel the next generation solutions. 
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